241 related articles for article (PubMed ID: 18449464)
21. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis.
Kawaguchi K; Oda Y; Saito T; Yamamoto H; Tamiya S; Takahira T; Miyajima K; Iwamoto Y; Tsuneyoshi M
J Pathol; 2003 Nov; 201(3):487-95. PubMed ID: 14595762
[TBL] [Abstract][Full Text] [Related]
23. Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean population.
Kim DS; Cha SI; Lee JH; Lee YM; Choi JE; Kim MJ; Lim JS; Lee EB; Kim CH; Park TI; Jung TH; Park JY
Lung Cancer; 2007 Oct; 58(1):1-6. PubMed ID: 17532092
[TBL] [Abstract][Full Text] [Related]
24. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer.
Gu J; Berman D; Lu C; Wistuba II; Roth JA; Frazier M; Spitz MR; Wu X
Clin Cancer Res; 2006 Dec; 12(24):7329-38. PubMed ID: 17189404
[TBL] [Abstract][Full Text] [Related]
25. CpG island methylation and expression of tumour-associated genes in lung carcinoma.
Dammann R; Strunnikova M; Schagdarsurengin U; Rastetter M; Papritz M; Hattenhorst UE; Hofmann HS; Silber RE; Burdach S; Hansen G
Eur J Cancer; 2005 May; 41(8):1223-36. PubMed ID: 15911247
[TBL] [Abstract][Full Text] [Related]
26. DNA methylation of multiple genes and clinicopathological relationship of non-small cell lung cancers.
Hanabata T; Tsukuda K; Toyooka S; Yano M; Aoe M; Nagahiro I; Sano Y; Date H; Shimizu N
Oncol Rep; 2004 Jul; 12(1):177-80. PubMed ID: 15201980
[TBL] [Abstract][Full Text] [Related]
27. Anthracotic index and DNA methylation status of sputum contents can be used for identifying the population at risk of lung carcinoma.
Konno S; Morishita Y; Fukasawa M; Shu Y; Wang D; Tanaka R; Minami Y; Iijima T; Noguchi M
Cancer; 2004 Dec; 102(6):348-54. PubMed ID: 15481085
[TBL] [Abstract][Full Text] [Related]
28. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
[TBL] [Abstract][Full Text] [Related]
29. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
30. Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients.
Liu Y; Lan Q; Siegfried JM; Luketich JD; Keohavong P
Neoplasia; 2006 Jan; 8(1):46-51. PubMed ID: 16533425
[TBL] [Abstract][Full Text] [Related]
31. p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients.
Ulivi P; Zoli W; Calistri D; Fabbri F; Tesei A; Rosetti M; Mengozzi M; Amadori D
J Cell Physiol; 2006 Mar; 206(3):611-5. PubMed ID: 16222700
[TBL] [Abstract][Full Text] [Related]
32. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer.
Ito M; Ito G; Kondo M; Uchiyama M; Fukui T; Mori S; Yoshioka H; Ueda Y; Shimokata K; Sekido Y
Cancer Lett; 2005 Jul; 225(1):131-9. PubMed ID: 15922865
[TBL] [Abstract][Full Text] [Related]
33. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer.
Hsu HS; Wen CK; Tang YA; Lin RK; Li WY; Hsu WH; Wang YC
Clin Cancer Res; 2005 Aug; 11(15):5410-6. PubMed ID: 16061855
[TBL] [Abstract][Full Text] [Related]
34. Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma.
Tanaka R; Wang D; Morishita Y; Inadome Y; Minami Y; Iijima T; Fukai S; Goya T; Noguchi M
Cancer; 2005 Feb; 103(3):608-15. PubMed ID: 15612080
[TBL] [Abstract][Full Text] [Related]
35. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer.
Kim JS; Kim JW; Han J; Shim YM; Park J; Kim DH
Cancer Res; 2006 Apr; 66(8):4049-54. PubMed ID: 16618724
[TBL] [Abstract][Full Text] [Related]
36. [Profile of methylation of certain tumor growth suppressing genes in non-small cell lung cancer].
Zemliakova VV; Zhevlova AI; Zborovskaia IB; Strel'nikov VV; Laktionov KK; Zaletaev DV; Nemtsova MV
Mol Biol (Mosk); 2003; 37(6):983-8. PubMed ID: 14714493
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways.
Murao K; Kubo Y; Ohtani N; Hara E; Arase S
Br J Dermatol; 2006 Nov; 155(5):999-1005. PubMed ID: 17034532
[TBL] [Abstract][Full Text] [Related]
38. Numerical abnormalities of chromosome 9 and p16CDKN2A gene deletion detected by FISH in non-small cell lung cancer.
Panani AD; Maliaga K; Babanaraki A; Bellenis I
Anticancer Res; 2009 Nov; 29(11):4483-7. PubMed ID: 20032395
[TBL] [Abstract][Full Text] [Related]
39. Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer.
Sirera R; Gil M; Blasco A; Cabrera A; Safont MJ; Iranzo V; Cayuela D; Rosell R; Camps C
Lung Cancer; 2008 Jul; 61(1):104-8. PubMed ID: 18243403
[TBL] [Abstract][Full Text] [Related]
40. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
